Spruce Biosciences Future Growth
Future criteria checks 2/6
Spruce Biosciences is forecast to grow earnings and revenue by 1.5% and 41.1% per annum respectively while EPS is expected to grow by 23.7% per annum.
Key information
1.5%
Earnings growth rate
23.7%
EPS growth rate
Biotechs earnings growth | 23.2% |
Revenue growth rate | 41.1% |
Future return on equity | n/a |
Analyst coverage | Good |
Last updated | 18 Mar 2024 |
Recent future growth updates
Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 2 | -71 | N/A | N/A | 5 |
12/31/2025 | 1 | -60 | N/A | N/A | 5 |
12/31/2024 | 5 | -50 | N/A | N/A | 7 |
12/31/2023 | 10 | -48 | -33 | -33 | N/A |
9/30/2023 | 7 | -49 | -34 | -34 | N/A |
6/30/2023 | 4 | -48 | -30 | -30 | N/A |
3/31/2023 | 2 | -47 | -42 | -42 | N/A |
12/31/2022 | N/A | -46 | -42 | -42 | N/A |
9/30/2022 | N/A | -44 | -40 | -40 | N/A |
6/30/2022 | N/A | -44 | -39 | -39 | N/A |
3/31/2022 | N/A | -44 | -39 | -39 | N/A |
12/31/2021 | N/A | -42 | -36 | -36 | N/A |
9/30/2021 | N/A | -41 | -35 | -35 | N/A |
6/30/2021 | N/A | -40 | -35 | -35 | N/A |
3/31/2021 | N/A | -34 | -30 | -30 | N/A |
12/31/2020 | N/A | -30 | -28 | -28 | N/A |
9/30/2020 | N/A | -24 | -21 | -21 | N/A |
6/30/2020 | N/A | -17 | -15 | -15 | N/A |
3/31/2020 | N/A | -15 | -14 | -14 | N/A |
12/31/2019 | N/A | -13 | -13 | -13 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: SPRB is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: SPRB is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: SPRB is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: SPRB's revenue (41.1% per year) is forecast to grow faster than the US market (8.2% per year).
High Growth Revenue: SPRB's revenue (41.1% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if SPRB's Return on Equity is forecast to be high in 3 years time